Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations

Movement Disorders

Volumn 28, Issue 14, 2013, Pages 1966-1971

  Alcalay, Roy N ^a   Mirelman, Anat ^b,c   Saunders Pullman, Rachel ^d,e   Tang, Ming X ^a   Mejia Santana, Helen ^a   Raymond, Deborah ^d   Roos, Ernest ^a   Orbe Reilly, Martha ^a   Gurevich, Tanya ^b   Bar Shira, Anat ^f   Gana Weisz, Mali ^f   Yasinovsky, Kira ^b   Zalis, Maayan ^b   Thaler, Avner ^b   Deik, Andres ^d   Barrett, Matthew James ^d   Cabassa, Jose ^d   Groves, Mark ^d   Hunt, Ann L ^d   Lubarr, Naomi ^d,e   San Luciano, Marta ^d   Miravite, Joan ^d   Palmese, Christina ^d,e   Sachdev, Rivka ^d,e   Sarva, Harini ^d   Severt, Lawrence ^d   Shanker, Vicki ^d,e   Swan, Matthew Carrington ^d   Soto Valencia, Jeannie ^d   Johannes, Brooke ^d   Ortega, Robert ^d   Fahn, Stanley ^a   Cote, Lucien ^a   Waters, Cheryl ^a   Mazzoni, Pietro ^a   Ford, Blair ^a   Louis, Elan ^a   Levy, Oren ^a   Rosado, Llency ^a   Ruiz, Diana ^a   Dorovski, Tsvyatko ^g   Pauciulo, Michael ^h   Nichols, William ^h   Orr Urtreger, Avi ^b,f   Ozelius, Laurie ⁱ   Clark, Lorraine ^a   Giladi, Nir ^b   Bressman, Susan ^d   Marder, Karen S ^a,g,j   more..

^a Columbia University ^*  (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d BETH ISRAEL MEDICAL CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^g Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j NewYork Presbyterian Hospital   (United States)

more..

Author keywords

Genetics; LRRK2; Parkinson; Postural instability and gait difficulty

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSYLCERAMIDASE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA;

AGE; AGED; ARTICLE; CLINICAL EVALUATION; COGNITIVE DEFECT; DEPRESSION; DISEASE DURATION; DRUG DOSE COMPARISON; DYSKINESIA; FEMALE; GENE MUTATION; GERIATRIC DEPRESSION SCALE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; JEW; LIMB TREMOR; MAJOR CLINICAL STUDY; MUSCLE CONTRACTION; MUSCLE RIGIDITY; ONSET AGE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; QUESTIONNAIRE; SEXUAL EDUCATION; SHUFFLING GAIT; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; UNITED STATES;

GENETICS; LRRK2; PARKINSON; POSTURAL INSTABILITY AND GAIT DIFFICULTY;

AGED; FEMALE; GENOTYPE; GLYCINE; HUMANS; JEWS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; QUESTIONNAIRES; REGRESSION ANALYSIS; SERINE; SEVERITY OF ILLNESS INDEX;

EID: 84889675482     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25647     Document Type: Article

References (32)

1. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600.
2. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
3. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590.
4. Aasly JO, Toft M, Fernandez-Mata I, et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005;57:762-765.
5. Orr-Urtreger A, Shifrin C, Rozovski U, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 2007;69:1595-1602.
6. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354:424-425.
7. Clark LN, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006;67:1786-1791.
8. Goldwurm S, Zini M, Di Fonzo A, et al. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord 2006;12:410-419.
9. Marras C, Schule B, Munhoz RP, et al. Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers. Neurology 2011;77:325-333.
10. Alcalay RN, Mejia-Santana H, Tang MX, et al. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol 2009;66:1517-1522.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
12. Nichols WC, Pankratz N, Marek DK, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009;72:310-316.
13. Gan-Or Z, Bar-Shira A, Dahary D, et al. Association of sequence alterations in the putative promoter of RAB7L1 with a reduced Parkinson disease risk. Arch Neurol 2012;69:105-110.
14. Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008;70:2277-2283.
15. Fahn S, Elton R; Members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent Developments in Parkinson's Disease, Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163, 293-304.
16. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
17. Lifshitz M, Dwolatzky T, Press Y. Validation of the Hebrew version of the MoCA test as a screening instrument for the early detection of mild cognitive impairment in elderly individuals. J Geriatr Psychiatry Neurol 2012;25:155-161.
18. D'Ath P, Katona P, Mullan E, Evans S, Katona C. Screening, detection and management of depression in elderly primary care attenders. I: the acceptability and performance of the 15 item Geriatric Depression Scale (GDS15) and the development of short versions. Fam Pract 1994;11:260-266.
19. Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 Geriatric Depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 1999;28:35-38.
20. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21:916-923.
21. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40:1529-1534.
22. Marder K, Levy G, Louis ED, et al. Accuracy of family history data on Parkinson's disease. Neurology 2003;61:18-23.
23. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
24. Saunders-Pullman R, Stanley K, San Luciano M, et al. Gender differences in the risk of familial parkinsonism: beyond LRRK2? Neurosci Lett 2011;496:125-128.
25. Bech S, Norremolle A, Winge K, et al. The lrrk2 p.Gly2019Ser mutation is uncommon in a Danish cohort with various neurodegenerative disorders. Parkinsonism Relat Disord 2011;17:398-399.
26. Yahalom G, Kaplan N, Vituri A, et al. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. Parkinsonism Relat Disord 2012;18:1039-1041.
27. Levy G, Louis ED, Cote L, et al. Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 2005;62:467-472.
28. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006;21:1123-1130.
29. van Nuenen BF, Helmich RC, Ferraye M, et al. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. Brain 2012;135:3687-3698.
30. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 2011;69:193-197.
31. Romanelli P, Esposito V, Schaal DW, Heit G. Somatotopy in the basal ganglia: experimental and clinical evidence for segregated sensorimotor channels. Brain Res Rev 2005;48:112-128.
32. Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord 2012;27:831-842.